Ibrutinib

• Background:

  Ibrutinib (936563-96-1) is a very potent (IC50 = 0.5nM) irreversible inhibitor of Bruton tyrosine kinase (BTK) that blocks activation of the B-cell antigen receptor (BCR) .1 Ibrutinib also potently inhibits several other kinases including BLK, BMS, FGR, EGFR, and ITK. It is a clinically useful drug to treat B cell cancers. It inhibits CLL cell migration and survival2,3 and downregulates expression of CD204. It enhanced antitumor immune responses in combination with anti PD-L1 blockade via its inhibition of ITK (IL2-inducible T-cell kinase) .5

• Conjugation:

  Unconjugated

• Buffer:

  White or off-white solid

• Storage Conditions:

  -20°C